UB Paderborn / Katalog / Suche / in CDI

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis

Annals of oncology, 2018-04, Vol.29 (4), p.895-902

2018

Link zum Volltext

Verfügbarkeit prüfen

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Annals of oncology, 2016-04, Vol.27 (4), p.619-624

2016

Link zum Volltext

Verfügbarkeit prüfen

Liquid biopsy accelerates precision medicine

Annals of oncology, 2023-04, Vol.34 (4), p.333-335

2023

Link zum Volltext

Verfügbarkeit prüfen

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Annals of oncology, 2021-09, Vol.32 (9), p.1148-1156

2021

Link zum Volltext

Verfügbarkeit prüfen

Expanding the landscape of actionable genomic alterations in metastatic breast cancer: comprehensive genomic profiling for all?

Annals of oncology, 2020-08, Vol.31 (8), p.967-969

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs

Oncogene, 2016-04, Vol.35 (14), p.1743-1749

2016

Link zum Volltext

Verfügbarkeit prüfen

The AURORA initiative for metastatic breast cancer

British journal of cancer, 2014-11, Vol.111 (10), p.1881-1887

2014

Link zum Volltext

Verfügbarkeit prüfen

First-in-human, first-in-class study of the CD44v6 inhibitor AMC303 as monotherapy in patients with advanced epithelial tumors

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii134

2018

Link zum Volltext

Verfügbarkeit prüfen

Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial

Annals of oncology, 2018-10, Vol.29, p.viii93-viii93

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical utility of complex multi-platform profiling in metastatic cancer patients

Annals of oncology, 2018-10, Vol.29, p.viii480-viii480

2018

Link zum Volltext

Verfügbarkeit prüfen

A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii418-viii418

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

Annals of oncology, 2018-10, Vol.29, p.viii654-viii654

2018

Link zum Volltext

Verfügbarkeit prüfen

SP-0207 INCIDENTS IN MEDICAL ONCOLOGY: MANAGEMENT AND CLINICAL IMPACT

Radiotherapy and oncology, 2012-05, Vol.103, p.S80-S80

2012

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study

ESMO open, 2023-12, Vol.8 (6), p.102041-102041, Article 102041

2023

Link zum Volltext

Verfügbarkeit prüfen

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer

ESMO open, 2022-12, Vol.7 (6), p.100651, Article 100651

2022

Link zum Volltext

Verfügbarkeit prüfen

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

The New England journal of medicine, 2021-04, Vol.384 (16), p.1529-1541

2021

Link zum Volltext

Verfügbarkeit prüfen

87 INVITED How to Optimise Strategies for Clinical Development of Combinations Based on Targeted Agents?

European journal of cancer (1990), 2011, Vol.47, p.S23-S23

2011

Link zum Volltext

Verfügbarkeit prüfen

108 CD70 (TNFSF7), a receptor involved in acute immune modulation of viral infection, is frequently overexpressed in solid and hematological malignancies

European journal of cancer (1990), 2014-11, Vol.50, p.39-39

2014

Link zum Volltext

Verfügbarkeit prüfen

528 Intratumoural treatment with LTX-, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours

European journal of cancer (1990), 2015-09, Vol.51, p.S113-S113

2015

Link zum Volltext

Verfügbarkeit prüfen

P08.03 2B3-101, GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS AND BREAST CANCER BRAIN METASTASES

Neuro-oncology (Charlottesville, Va.), 2014-09, Vol.16 (suppl 2), p.ii50-ii51

2014

Link zum Volltext

Verfügbarkeit prüfen

EP-1054 ADJUVANT CHEMORADIATION IN PANCREATIC CANCER: A SINGLE INSTITUTION EXPERIENCE

Radiotherapy and oncology, 2012-05, Vol.103, p.S411-S412

2012

Link zum Volltext

Verfügbarkeit prüfen

A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer

Medical oncology (Northwood, London, England), 2011-12, Vol.28 (Suppl 1), p.142-151

2011

Link zum Volltext

Verfügbarkeit prüfen

PO-1185 Targeting therapy-resistant metastatic clones with SBRT in oligoprogressive breast cancer

Radiotherapy and oncology, 2022-05, Vol.170, p.S1005-S1005

2022

Link zum Volltext

Verfügbarkeit prüfen

58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment

Annals of oncology, 2022-05, Vol.33, p.S148-S149

2022

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Liquid biopsy accelerates precision medicine

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Expanding the landscape of actionable genomic alterations in metastatic breast cancer: comprehensive genomic profiling for all?

Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs

The AURORA initiative for metastatic breast cancer

First-in-human, first-in-class study of the CD44v6 inhibitor AMC303 as monotherapy in patients with advanced epithelial tumors

Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial

Clinical utility of complex multi-platform profiling in metastatic cancer patients

A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

SP-0207 INCIDENTS IN MEDICAL ONCOLOGY: MANAGEMENT AND CLINICAL IMPACT

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

87 INVITED How to Optimise Strategies for Clinical Development of Combinations Based on Targeted Agents?

108 CD70 (TNFSF7), a receptor involved in acute immune modulation of viral infection, is frequently overexpressed in solid and hematological malignancies

528 Intratumoural treatment with LTX-, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours

PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment

P08.03 2B3-101, GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS AND BREAST CANCER BRAIN METASTASES

EP-1054 ADJUVANT CHEMORADIATION IN PANCREATIC CANCER: A SINGLE INSTITUTION EXPERIENCE

A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer

PO-1185 Targeting therapy-resistant metastatic clones with SBRT in oligoprogressive breast cancer

58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment

Suchergebnisse filtern